Eli Lilly and Company LLY reported fourth-quarter 2025 adjusted earnings per share (“EPS”) of $7.54, which beat the Zacks ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also looks ripe to announce a stock split. Eli Lilly's shares look attractive ...

In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today. The big story around Eli Lilly is the success of its GLP-1 drugs Mounjaro (for diabetes) and Zepbound (for weight ...